R
Rose Ann Ferre
Researcher at Pfizer
Publications - 18
Citations - 1304
Rose Ann Ferre is an academic researcher from Pfizer. The author has contributed to research in topics: Cyclin-dependent kinase & CDK inhibitor. The author has an hindex of 11, co-authored 18 publications receiving 793 citations.
Papers
More filters
Journal ArticleDOI
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Robert Louis Hoffman,Robert Steven Kania,Jay F. Davies,Rose Ann Ferre,Ketan S. Gajiwala,Mingying He,Robert J. Hogan,Kirk Kozminski,Lilian Y. Li,Jonathan W. Lockner,Jihong Lou,Michelle T. Marra,Lennert J. Mitchell,Brion W. Murray,James A. Nieman,Stephen Noell,Simon Paul Planken,Thomas Rowe,Kevin Ryan,George J. Smith,James Solowiej,Claire M. Steppan,Barbara Taggart +22 more
TL;DR: Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
Journal ArticleDOI
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Ping Chen,Nathan V. Lee,Wenyue Hu,Meirong Xu,Rose Ann Ferre,Hieu Lam,Simon Bergqvist,James Solowiej,Wade Diehl,You-Ai He,Xiu Yu,Asako Nagata,Todd VanArsdale,Brion W. Murray +13 more
TL;DR: Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development is often hindered by toxicities and inadequate efficacy, so understanding the molecular components of potency and selectivity facilitates rational design of future generations of kinase-directed drugs.
Posted ContentDOI
The Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
Robert M. Hoffman,Robert Steven Kania,Jay F. Davies,Rose Ann Ferre,Ketan S. Gajiwala,Mingying He,Robert J. Hogan,Kirk Kozminski,Lilian Y. Li,Jonathan W. Lockner,Jihong Lou,Michelle T. Marra,Mitchell Lennert J,Brion W. Murray,James A. Nieman,Stephen Noell,Simon Paul Planken,Thomas Rowe,Kevin M. Ryan,George J. Smith,James Solowiej,Claire M. Steppan,Barbara Taggart +22 more
TL;DR: Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
Journal ArticleDOI
The Crystal Structure of the RNA-Dependent RNA Polymerase from Human Rhinovirus: A Dual-Function Target for Common Cold Antiviral Therapy
Robert A. Love,Karen A. Maegley,Xiu Yu,Rose Ann Ferre,Laura Lingardo,Wade Diehl,Hans E. Parge,Peter S. Dragovich,Shella A. Fuhrman +8 more
TL;DR: HRV 3Dpol provides the first complete view of a picornaviral RdRp and resembles that of RdRps from hepatitis C virus (HCV) and rabbit hemorrhagic disease virus (RHDV) despite very low sequence homology.
Journal ArticleDOI
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.
Peter S. Dragovich,Thomas J. Prins,Ru Zhou,Theodore O. Johnson,Ye Hua,Hiep T. Luu,Sylvie K. Sakata,Edward L. Brown,Fausto Maldonado,Tove Tuntland,Caroline A. Lee,Shella A. Fuhrman,Leora S. Zalman,Amy K. Patick,David A. Matthews,Ellen Y. Wu,Ming Guo,Bennett Chaplin Borer,Naresh K. Nayyar,Moran Terence Jarold,Lijian Chen,Paul A. Rejto,Peter W. Rose,Mark Christopher Guzman,Elena Z. Dovalsantos,Steven Lee,Kevin Scott Mcgee,Michael Mohajeri,Andreas Liese,Junhua Tao,Maha B. Kosa,Bo Liu,Minerva R. Batugo,Jean-Paul R. Gleeson,Zhen Ping Wu,Jia Liu,James W. Meador,Rose Ann Ferre +37 more
TL;DR: The optimization of the pharmacokinetic performance of various 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors following oral administration to either beagle dogs or CM-monkeys is described.